近5日资金流向一览见下表： 证券之星消息，截至2026年2月9日收盘，惠泰医疗(688617)报收于229.38元，下跌0.27%，换手率 0.52%，成交量7315.0手，成交额1.67亿元。 2月9日的资金流向数据方面，主力资金净流入1289.18万元，占总成交额7.71%，游资资金净流出 1122.48万元，占总成交额6.71%，散户资金净流出166.7万元，占总成交额1.0%。 惠泰医疗2025年三季报显示，前三季度公司主营收入18.67亿元，同比上升22.47%；归母净利润6.23亿 元，同比上升18.02%；扣非净利润6.02亿元，同比上升18.5%；其中2025年第三季度，公司单季度主营 收入6.54亿元，同比上升24.77%；单季度归母净利润1.98亿元，同比上升6.77%；单季度扣非净利润1.91 亿元，同比上升6.1%；负债率12.24%，投资收益1390.22万元，财务费用-811.65万元，毛利率73.19%。 惠泰医疗（688617）主营业务：公司是一家专注于电生理和血管介入医疗器械的研发、生产和销售的高 新技术企业,已形成了以完整冠脉通路和电生理医疗器械为主导,外周血管和神经介入医 ...

证券之星消息，截至2026年2月9日收盘，春立医疗(688236)报收于23.0元，下跌0.35%，换手率0.53%， 成交量1.52万手，成交额3498.88万元。 2月9日的资金流向数据方面，主力资金净流出63.27万元，占总成交额1.81%，游资资金净流入391.14万 元，占总成交额11.18%，散户资金净流出327.87万元，占总成交额9.37%。 春立医疗融资融券信息显示，融资方面，当日融资买入524.38万元，融资偿还376.73万元，融资净买入 147.65万元。融券方面，融券卖出400.0股，融券偿还0.0股，融券余量800.0股，融券余额1.84万元。融 资融券余额4854.82万元。 近5日融资融券数据一览见下表： | 日期 | 涨跌幅 | | 融资余额(元) 融资净买入(元) 融券余量(股) | | (品)用品要求量 | 融资融券余额(元) | | --- | --- | --- | --- | --- | --- | --- | | 2026-02-09 | -0.35% | 4852.98万 | 147.65万 | 800.0 | 400.0 | 4854.82万 | | 2026 ...

（来源：中国医药报） 通过多层次、系统化的严监管举措，海南省药品安全基本面持续稳固。去年，未发生区域性、系统性药 品安全风险，企业质量管理体系不断优化；已有10家医药企业通过国际相关认证，产业竞争力稳步提 升。 优化检查流程 减轻企业负担 "监管既要守牢安全底线，也要为产业发展留足空间"，这是海南自贸港医药产业快速发展对药品监管提 出的现实要求。去年8月，《海南省药品监督管理局关于优化药品注册生产现场检查若干措施的通告》 （以下简称《通告》）发布实施，优化多项检查流程，涵盖部分行政许可检查、再注册恢复生产检查、 药品GMP（生产质量管理规范）符合性检查及变更制剂生产场地检查等。 转自：中国医药报 □ 卢进梅 近年来，海南省药品查验中心立足全省医药产业快速发展和海南自贸港封关运作的新形势，聚焦监管效 能与产业服务双提升，通过分级监管、优化流程、强化服务等举措，努力打造自贸港药品检查新范式， 为药品安全与产业高质量发展注入新动能。 创新监管机制 防控药品风险 面对有限的监管资源与日益复杂的监管形势，海南省药品查验中心主动求变，聚焦医药产业薄弱环节， 持续拓展检查广度、深挖检查深度、加大检查力度，织密药品安全风险防 ...

Core Insights - The article discusses the organization of an online and offline training session by the Jiangmen Market Supervision Administration in Guangdong Province, focusing on the newly revised Medical Device Good Manufacturing Practice (GMP) [1] - The training aims to enhance compliance management and regulatory enforcement capabilities among regulatory personnel and company representatives [1] Group 1: Training and Implementation - The training emphasizes the core requirements of the Medical Device GMP, highlighting the background of the revisions, major changes, and key implementation points [1] - The session aims to provide a clear understanding of the five major highlights of the Medical Device GMP through accessible explanations [1] Group 2: Ongoing Support and Supervision - The Jiangmen Market Supervision Administration plans to continue its efforts in promoting the Medical Device GMP through regular, tiered training and guidance [1] - There will be targeted support for key positions in research and development, production, and quality management within companies [1] - The administration will incorporate the implementation of Medical Device GMP into daily regulatory activities, focusing on high-risk products and companies with weak quality management [1]

Core Viewpoint - The article highlights the successful development and approval of a domestically produced ECMO (Extracorporeal Membrane Oxygenation) device by Shandong Hengxin Medical Equipment Co., showcasing the company's commitment to innovation and the support from regulatory authorities in China [2][4]. Company Overview - Shandong Hengxin Medical Equipment Co. is led by Liu Shuqin, a retired professor and expert in magnetic levitation, who aims to accelerate the development of portable and intelligent ECMO devices to fill domestic market gaps [2][3]. - The company has successfully obtained the third-class medical device registration certificate for its ECMO, marking it as the sixth approved ECMO product in China and the first in Shandong [2][3]. Research and Development - The R&D team at Hengxin Medical comprises experts from various fields, including mechanical, electrical, magnetic, control, and materials engineering, as well as medical professionals from critical care and emergency medicine [3]. - The ECMO device's blood flow control precision is achieved at 20 ml/min, with a temperature difference of 0.1 degrees Celsius, surpassing the regulatory requirements and reaching international standards [3]. Regulatory Support - The Shandong Provincial Drug Administration has provided significant support to Hengxin Medical, guiding the company through product testing, clinical trials, and quality management system establishment [4]. - The recent inclusion of ECMO in the National Medical Products Administration's priority approval list for high-end medical devices is seen as a major advantage for Hengxin Medical [4].

Group 1 - On February 9, 2026, Zhendemedical (603301) closed at 80.69 yuan, up 10.01%, reaching the daily limit with a turnover rate of 1.76% and a trading volume of 46,800 lots, resulting in a transaction amount of 373 million yuan [1] - The net inflow of main funds on February 9 was 75.55 million yuan, accounting for 20.25% of the total transaction amount, while retail investors experienced a net outflow of 29.04 million yuan, representing 7.78% of the total transaction amount [1] - Over the past five days, the stock has shown a price increase of 10.01% on February 9, with a previous increase of 4.86% on February 6, and a decrease of 0.63% on February 5 [2] Group 2 - As of February 9, 2026, the financing balance for Zhendemedical was 1.372 billion yuan, with a net repayment of 104 million yuan on that day [3] - The stock's financing buy on February 9 was 39.69 million yuan, while the financing repayment was 143 million yuan [3] - The stock's short selling on February 9 involved 100 shares sold, with a remaining short selling balance of 1.55 million shares valued at 1.2507 million yuan [3] Group 3 - Zhendemedical's total market value is 21.45 billion yuan, with a net asset value of 5.985 billion yuan and a net profit of 203 million yuan [5] - The company's price-to-earnings ratio (P/E) is 79.18, while the industry average is 65.68, indicating a higher valuation compared to peers [5] - The gross profit margin for Zhendemedical is 33.93%, significantly lower than the industry average of 50.61%, and the net profit margin is 6.61%, compared to the industry average of 9.71% [5] Group 4 - In the third quarter of 2025, Zhendemedical reported a main revenue of 3.184 billion yuan, a year-on-year increase of 1.88%, while the net profit decreased by 33.91% to 203 million yuan [5] - The company's debt ratio stands at 28.78%, with investment income of 8.4885 million yuan and financial expenses of 26.0941 million yuan [5] - The company specializes in the production and sale of basic care, surgical infection control, pressure treatment and fixation, stoma and modern wound care, and infection control protection products [5]

Core Viewpoint - The stock of Aojing Medical (688613) has shown a significant increase, closing at 24.17 yuan on February 9, 2026, with an 8.58% rise, indicating positive market sentiment towards the company [1]. Group 1: Stock Performance - On February 9, 2026, Aojing Medical's trading volume was 79,600 hands, with a total transaction amount of 189 million yuan [1]. - The stock's turnover rate was 5.81%, reflecting active trading [1]. Group 2: Capital Flow - On February 9, 2026, the net inflow of main funds was 2.45 million yuan, accounting for 1.29% of the total transaction amount, while retail investors saw a net inflow of 2.69 million yuan, representing 1.42% of the total [1]. - Over the past five days, the financing data showed a net purchase of 1.41 million yuan on that day, with a cumulative net purchase of 5.72 million yuan over three days [2]. Group 3: Financial Performance - For the first three quarters of 2025, Aojing Medical reported a main revenue of 156 million yuan, a year-on-year increase of 5.22%, and a net profit attributable to shareholders of 13.94 million yuan, up 185.19% [3]. - In the third quarter of 2025, the company achieved a single-quarter main revenue of 56.02 million yuan, a 16.54% increase year-on-year, and a net profit of 5.97 million yuan, reflecting a 237.64% rise [3]. - The company's gross profit margin stood at 68.9%, indicating strong profitability in its operations [3].

智通财经APP获悉，据港交所2月9日披露，杭州糖吉医疗科技股份有限公司(简称：糖吉医疗)向港交所 主板递交上市申请书，工银国际、财通国际为其联席保荐人。 | 纂]項下的[编纂]數目 : [编纂]股H股(視乎[编纂] | | | --- | --- | | 行使與合向定) | | | [编纂]數目 | : [编纂]股H股(可予[编纂]) | | [编纂]數目 | : [编纂]股H股(可于编纂]及 | | 視乎[编纂]行使與否而定) | | | 最高[编纂] .. | 每股H股[编纂]港元,另加1.0%經紀冊金、 | | 0.0027%證監會交易微費、0.00015% | | | 會財局交易徵費及0.00565%香港聯交所 | | | 交易費(須於申請時以港元繳足, | | | 多織股款可予想還) | | | 面值 | : 每股H股人民幣0.10元 | | 【湯養】 | : [编纂] | | 聯席保薦人 ·[编纂] | | 公司简介 招股书披露，糖吉医疗是一家立足中国的医疗器械公司，专注于为代谢性疾病的治疗及全周期管理提供 创新解决方案。公司战略构建了涵盖肥胖及代谢性疾病治疗器械与适配器械及全周期管理产品的产品管 ...

Core Viewpoint - The company held its 43rd meeting of the 5th Board of Directors, where it approved two key proposals regarding equity transfer and participation in restructuring investment bidding [1][5]. Group 1: Equity Transfer Proposal - The company agreed to the transfer of 1% unpaid equity of its subsidiary, Shandong Buchang Guanyou Medical Equipment Co., Ltd., from shareholder Liu Anan to Zhu Binbin at a price of RMB 0, while waiving its right of first refusal [2][11]. - After the transfer, the company's ownership in Buchang Guanyou will remain at 90% [11][13]. - The transaction does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations, and does not require shareholder approval [11][12]. Group 2: Restructuring Investment Bidding Proposal - The company plans to participate in the bidding for restructuring investor qualifications to expand its presence in the traditional Chinese medicine sector, aligning with its strategic vision of becoming "China's Johnson & Johnson" [5][18]. - Due to the uncertainties and commercial confidentiality involved in this transaction, specific details will be disclosed after the bidding process concludes [5][18]. - The proposal was also approved by the Board's Strategic and Investment Committee before being presented to the Board [3][6].

Core Viewpoint - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 12,700 shares on February 9, indicating a fluctuating interest from these investors in the company [1] Group 1: Southbound Fund Activity - Over the past five trading days, there were three days of net reductions in holdings by southbound funds, totaling a net decrease of 674,000 shares [1] - In the last twenty trading days, there were ten days of net reductions, with a cumulative net decrease of 769,000 shares [1] - Currently, southbound funds hold 41,477,300 shares of Chuangli Medical, accounting for 43.59% of the company's total issued ordinary shares [1] Group 2: Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. specializes in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]